This excerpt taken from the EYE 8-K filed Oct 25, 2007.
Earlier this month, AMO launched a global campaign designed to educate contact lens wearers about proper lens cleaning techniques. The campaign coincides with the retail availability of AMOs Complete® Multipurpose Solution Easy RubTM formula, which commenced shipments to U.S., European and Japanese markets in August and September. Shipments to Asia Pacific markets are now underway. Practitioner promotion began in October. The formulation provides powerful disinfection while promoting tear film stability and long-lasting comfort.
In September, AMO introduced the Tecnis® 1-Piece IOL to the European market. The new lens offers existing Tecnis® IOL benefits and claims for reduced spherical aberration and improved functional vision in an innovative and easy-to-use design. AMO expects the Tecnis® 1-Piece IOL to contribute to continued migration of IOL sales to the Tecnis® platform, which represented 56 percent of the companys monofocal IOL sales in the third quarter. AMO expects the Tecnis® 1-Piece IOL to be available to U.S. surgeons in the first half of 2008.
In addition, the company introduced the Tecnis® Multifocal Acrylic IOL to the European market. This diffractive lens, previously available to European surgeons on a silicone platform, allows a full range of quality vision and is designed to correct the two highest-order aberrations: spherical aberration and chromatic aberration. AMO continues to expect the Tecnis® Multifocal IOL to be available to U.S. surgeons in 2009. Also in September, the company introduced the WhiteStar Signature phacoemulsification system with Fusion Fluidics to the European market, following the successful U.S. launch of the lens removal technology last spring. This new system combines the proven performance of AMOs WhiteStar® technology with the safety of an advanced dual pump fluidic system.
During the quarter, the National Aeronautics and Space Agency (NASA) approved the companys LASIK technologies for use on U.S. astronauts. The NASA decision was made following review of extensive military clinical data, which showed superior safety and vision when using AMOs CustomVue® and IntraLase® technologies in combination.